Tag Archives: Elemer Piros

Cantor Fitzgerald Keeps a Hold Rating on Arrowhead Research (ARWR)

Cantor Fitzgerald analyst Elemer Piros maintained a Hold rating on Arrowhead Research (ARWR – Research Report) today and set a price target of $50.00. The company’s shares closed last Monday at $48.17, close to its 52-week high of $49.78. According

Cantor Fitzgerald Reaffirms Their Buy Rating on Abeona Therapeutics (ABEO)

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Abeona Therapeutics (ABEO – Research Report) today and set a price target of $29. The company’s shares opened today at $7.11, close to its 52-week low of $6.26. Piros observed:

Cantor Fitzgerald Reaffirms Their Buy Rating on Apellis Pharmaceuticals Inc (APLS)

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Apellis Pharmaceuticals Inc (APLS – Research Report) today and set a price target of $52. The company’s shares opened today at $19.01. Piros said: “: We are reiterating our OW

Cantor Fitzgerald Reaffirms Their Buy Rating on Rigel (RIGL)

In a report released yesterday, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Rigel (RIGL – Research Report), with a price target of $7. The company’s shares closed yesterday at $2.32, close to its 52-week low of $1.96.

Cantor Fitzgerald Reaffirms Their Buy Rating on Marinus (MRNS)

In a report released today, Elemer Piros from Cantor Fitzgerald maintained a Buy rating on Marinus (MRNS – Research Report), with a price target of $22. The company’s shares closed yesterday at $4.94. Piros observed: “Given the compelling Phase 2

Analysts Conflicted on These Healthcare Names: PolarityTE Inc (NASDAQ: PTE), Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH) and Hologic (NASDAQ: HOLX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on PolarityTE Inc (PTE – Research Report), Spring Bank Pharmaceuticals Inc (SBPH – Research Report) and Hologic (HOLX – Research Report). PolarityTE Inc (PTE) Cantor Fitzgerald